Evidence map›Paper›PMID 41007201›Full record

ArticleBioengineering (Basel, Switzerland)2025

Defining a Simplified Process in Yeast for Production of Enveloped VLP Dengue Vaccine.

Salomé de Sá Magalhães, Stephen A Morris, Shinta Kusumawardani, Acep Riza Wijayadikusumah, Neni Nurainy, Eli Keshavarz-Moore

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Salomé de Sá MagalhãesDepartment of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK.ORCID 0009-0009-1956-765X
Stephen A MorrisDepartment of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK.ORCID 0000-0002-7640-8657
Shinta KusumawardaniPT Biofarma, Bandung 40161, Indonesia.
Acep Riza WijayadikusumahPT Biofarma, Bandung 40161, Indonesia.ORCID 0000-0003-1104-9259
Neni NurainyPT Biofarma, Bandung 40161, Indonesia.ORCID 0000-0002-6130-4855
Eli Keshavarz-MooreDepartment of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK.ORCID 0000-0002-3918-1959

Funding

Engineering and Physical Sciences Research Council Vax-Hub, EP/R013756/1
6 · The paper itself

Abstract

Dengue is a rapidly spreading mosquito-borne viral infection, with increasing reports of outbreaks globally. According to the World Health Organization (WHO), by 30 April 2024, over 7.6 million dengue cases were reported, including 3.4 million confirmed cases, more than 16,000 severe cases, and over 3000 deaths. As dengue remains endemic in many regions, there is a critical need for the development of new vaccines and manufacturing processes that are efficient, cost-effective, and capable of meeting growing demand. In this study, we explore an alternative process development pathway for the future manufacturing of a dengue vaccine, utilizing

Indexed as

dengue diseaseKomagataella phaffiiLMICsplatform technologyvaccineVLPs

Identifiers

PMID41007201
PMCPMC12467798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.